BNTX - Erytech Spikes On Fast Track And Other News: The Good Bad And Ugly Of Biopharma
Erytech Pharma Gets FDA Boost for Eryaspase
Erytech Pharma SA (ERYP) announced that the FDA has granted Fast Track status to its lead drug candidate Eryaspase. The drug candidate is being evaluated as the second line treatment for metastatic pancreatic cancer. With Fast Track designation, the company has higher interaction with the FDA review team and the marketing application goes through rolling review process. The company also reported that it has achieved 75 percent enrollment for its Phase 3 clinical trial TRYbeCA-1.
Erytech Pharma reported that its lead drug candidate is being assessed for second-line